In:
Stroke, Ovid Technologies (Wolters Kluwer Health), Vol. 42, No. 9 ( 2011-09), p. 2633-2635
Kurzfassung:
Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. Methods— The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Results— Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P =0.0022; non-tPA, P =0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P 〈 0.0001; non-tPA, P =0.0019). Conclusions— Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.
Materialart:
Online-Ressource
ISSN:
0039-2499
,
1524-4628
DOI:
10.1161/STROKEAHA.111.618215
Sprache:
Englisch
Verlag:
Ovid Technologies (Wolters Kluwer Health)
Publikationsdatum:
2011
ZDB Id:
1467823-8